Sign Up Now for Dodge Drugs Dodge Ball Tournament


PMP will be helping to sponsor a Dodge Drugs dodge ball tournament that is being planned by a group of youth from St. Pius X / St. Leo (SPSL) School in Omaha. In addition to this, proceeds from this tournament will be going to benefit PMP!  SPSL’s  Destination Imagination (DI) Team has chosen service learning this year as their topic with the goal of raising money to prevent substance abuse.  Destination Imagination is a non-profit, worldwide creativity competition.  The teams compete in a regional, state, and possibly world competition in their selected topic.  This year, SPSL’s DI Team chose service learning and after holding their community event (Dodge Drugs dodge ball tournament) they will develop a presentation and present in the regional tournament in March.  We are so very excited to partner with them!

The tournament will be on Saturday, January 23, 2016 with a Youth division from 5-7:30pm and Adult division from 7:30-10pm.  Teams will be comprised of 6 people and the registration fee is $5 / person or $30 / team.  This is a great opportunity to participate in a youth-led event that will benefit our coalition and get some exercise (or take out your frustrations :-))at the same time! Please see the flyer for more details and to register.

Dodge Drugs Registration Form


Epidiolex Showing Promise?


Results of 3 uncontrolled studies of Epidiolex seem to show promise for patients with epilepsy.  Here’s an excerpt and summary of Epidiolex results released yesterday at the American Epilepsy Society meeting.  As the researchers caution, these were uncontrolled studies, and more research is required via clinical trials due to conclude in about 6 months.  This is great news for those children and their families who are suffering from debilitating seizures!

This is also key for states to see this news and to put their plans on hold to legalize marijuana for medical purposes.  As these clinical trial results get released, there likely will not be a need for states to take matters into their own hands any longer, as the FDA may be approving some actual medicine for these conditions.

“After three months of treatment, the frequency of all seizures was reduced by a median of 45 percent in all participants. Almost half (47%) of the participants in the study experienced a 50 percent or greater reduction in seizures and nine percent of patients were seizure-free. Among specific patient populations, DS (Dravet Syndrome) patients had a 62 percent reduction in seizures and 13 percent were seizure-free. Patients with LGS (Lennox-Gastaut Syndrome) experienced a 71 percent reduction in atonic seizures.”


© Copyright Prevention Means Progress - Website Design by REBEL INTERACTIVE